Evidence map›Paper›PMID 40766894›Full record

ArticleClinical hypertension2025

Optimizing systolic blood pressure targets for elderly hypertensive patients: a meta-analysis of mortality, cardiovascular outcomes, and adverse events.

Sungjoon Park, Ein-Soon Shin, Sang-Hyun Ihm, Hae-Young Lee

Abstract read
In one paragraph

Article in Clinical hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Challenges and Perspectives in Optimising the Treatment of Arterial Hypertension: Role of the Ramipril-Amlodipine-Hydrochlorothiazide Single-Pill Combination.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sungjoon ParkDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-0273-5145
Ein-Soon ShinDepartment of Preventive Medicine and Public Health, Ajou University School of Medicine, Suwon, Republic of Korea.ORCID https://orcid.org/0000-0002-5086-6086
Sang-Hyun IhmDivision of Cardiology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Republic of Korea.ORCID https://orcid.org/0000-0001-5017-5421
Hae-Young LeeDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-9521-4102

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hypertension is a common health issue among elderly populations, substantially increasing morbidity and mortality risks. This meta-analysis aimed to determine optimal systolic blood pressure (SBP) targets in elderly hypertensive patients and their effects on clinical outcomes. Methods: We conducted a systematic search of PubMed, Embase, and the Cochrane Library to identify randomized controlled trials involving antihypertensive therapy in participants aged 60 years and older. Mortality, cardiovascular events, and significant adverse events data were extracted and analyzed using random-effects models. Results: The analysis included 24 studies, with 9 specifically examining elderly participants aged 60 and older. Targeting a lower SBP of less than 140 mmHg was associated with significant reductions in primary outcome events (relative risk [RR], 0.69; 95% confidence interval [CI], 0.56-0.86), all-cause mortality (RR, 0.64; 95% CI, 0.49-0.83), cardiovascular mortality (RR, 0.59; 95% CI, 0.39-0.87), and stroke (RR, 0.68; 95% CI, 0.47-0.98; I Conclusions: In elderly hypertensive patients, lower SBP targets correlate with improved clinical outcomes, including reduced mortality and cardiovascular events. Nonetheless, the heightened risk of adverse effects underscores the need for careful, individualized treatment strategies. Additional research is warranted to refine these targets and achieve a balance between therapeutic efficacy and safety.

Indexed as

ElderlyHypertension

Identifiers

PMID40766894
PMCPMC12322049

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.